Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice - Wikidata - awgldk - TriplyDB

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

http://www.wikidata.org/entity/Q36404114

about

The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquiti Role of bone-anabolic agents in the treatment of breast cancer bone metastases Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice Advances in the understanding of myeloma bone disease and tumour growth.Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study The effects of proteasome inhibitors on bone remodeling in multiple myeloma.The corepressor Tle4 is a novel regulator of murine hematopoiesis and bone development.A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.Bortezomib in the management of multiple myeloma.A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.Targeted delivery of mesenchymal stem cells to the bone Pasteurella multocida toxin prevents osteoblast differentiation by transactivation of the MAP-kinase cascade via the Gα(q/11)--p63RhoGEF--RhoA axis.Novel functions for NFκB: inhibition of bone formation Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Sources of adult mesenchymal stem cells applicable for musculoskeletal applications - a systematic review of the literature Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation.Bone anabolic agents for the treatment of multiple myeloma.Targeting bone as a therapy for myeloma.The 26S proteasome complex: an attractive target for cancer therapy Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1.Myeloma as a model for the process of metastasis: implications for therapy Bone marrow microenvironment and the identification of new targets for myeloma therapy.Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells.Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity.Effects of proteasome inhibitors on bone cancer The leukemic stem cell niche: current concepts and therapeutic opportunities.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Lysine-specific demethylase 1 inhibitor rescues the osteogenic ability of mesenchymal stem cells under osteoporotic conditions by modulating H3K4 methylation.Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?NF-κB RelB negatively regulates osteoblast differentiation and bone formation.

P2860

Q24303919-2313FFE0-5460-4091-AA69-A05146D508B7 Q26822732-8EB8719A-CD0F-49C1-83D9-B40292DDF61A Q28082335-0D243EBA-28AB-4BC5-9A6B-195685450136 Q28485441-34EE8EAE-B621-4F52-85EA-5C14019BFC1D Q33829022-D43E0E59-EBD0-46CB-9F44-F720F6D5D924 Q33891364-97F95F2C-5B67-411B-BAE5-AF236EE54273 Q33918020-32E9CA1B-C243-447B-847E-B877862E3BFA Q34083894-BBA90962-0681-4C3F-9CF3-5F051B809BF2 Q34203659-FD79E81F-0388-4A9F-9318-7D9B4BA0AFA8 Q34269238-FA0392CA-199B-4897-8BFD-4C02AF9FA309 Q34418462-472BFA2B-56BE-4C2A-B892-4545D7B9326D Q34543089-019744C4-EE87-4489-8E6D-0A41F5D57FB5 Q34716765-55423532-DD02-4F04-9E58-3E55A39C96EA Q34733617-96B1F929-A67F-4A00-AE7B-5C71C47082CA Q34806538-B749738F-2486-4EA5-A77F-85D51252B845 Q34997270-3CC02938-A1CC-47E1-849E-D837487A0970 Q35097319-116871FC-C6C0-4861-9621-C58A2CC83A72 Q35146617-4873150D-D839-42D4-9A94-26B5331C2C52 Q35155505-7EC8F727-A697-4D64-BB56-783E239B99E5 Q35603116-2A890105-20C2-4BF9-8FC8-B0CCD240772B Q35603128-B50E08BF-32B6-4AD0-8CD7-BB5FAF6E1906 Q35624079-39C1484C-A12A-469F-9EE0-E8BEAA16E9C8 Q36065663-DDD4D2D3-992A-4427-BDE7-93EE9EBFC4ED Q36079800-C7939F23-08CB-4385-A4A6-24D682822CFD Q36162703-359E04B4-0E04-4AC7-A26E-779C9EA10ECD Q36282399-B069D448-ED25-4C3B-8876-E1B3CB17AD13 Q36709283-6397C132-1EF6-4D4C-9D44-C2ED074F00A9 Q36800940-D12C6886-4DC3-403F-8FAA-8ECB4B4EE8F7 Q36954453-444CDA0F-F717-43D0-A019-175D87160978 Q37034189-CD3BC162-5A47-4B4B-8B2E-1CF6FDF0C1C1 Q37128607-B36B314B-2562-40A9-A3AF-7C182D0459BB Q37166798-24F0DE4C-9AC8-410C-9C51-00C1BBF5A059 Q37176560-4AB57D8B-7DD8-46D5-A9D8-23BB51993D25 Q37209135-B9F1486E-C431-4AE3-A1AB-6842EFD285C7 Q37281071-0A8A2ADE-DDCC-4A04-92BD-14C88DB95154 Q37295129-7543B273-62C5-48AB-BFD8-93B48F4A7092 Q37348247-4DF85361-247D-4675-B971-A4CB5C7FA51A Q37538464-2788D3C1-2590-49C0-8FF2-11FD1A04E037 Q37617724-85AAF1F4-FB4A-4A72-88B0-6DEE45EB91F4 Q37653034-1DDDEA8C-DD38-4527-8359-4454D6ED7481

P2860

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

http://www.wikidata.org/entity/Q36404114

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@ast

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@en

type

label

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@ast

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@en

prefLabel

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@ast

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@en

P1433

Q36404114-E83FE327-85AA-4E16-892E-43A5BAF7FE99

P1476

Q36404114-E9F7367C-AD5D-4933-9328-0A8FA2836090

P2093

Q36404114-09150356-2C73-42E0-9E40-CF8E86A880AC

Q36404114-272660D0-F951-4B4D-A3DE-EC38A2906183

Q36404114-29A5FFF9-35CB-4719-B338-4B8292BCCDB8

Q36404114-2FDC8D7E-CC76-4360-BA55-7CA844D53E5F

Q36404114-3CA52BCA-F328-4FB8-817C-7116B137ADF4

Q36404114-55C433DA-5416-486E-B0AA-52A9CAD584AC

Q36404114-774EE974-579D-4B0B-8BED-B62875B9C033

Q36404114-85656B04-C294-477D-9BB3-4D1179262C57

Q36404114-8803A2D2-3B8A-46C1-BAEF-223345FE8388

Q36404114-88C20F1E-E7A9-416E-8848-5B12A681BC8A

P2860

Q36404114-07C5AEBC-9545-4ACD-AE0B-370F8C1241EB

Q36404114-13825C58-0E5D-41BA-981D-8787B489BD82

Q36404114-14B7592C-E612-441E-B497-E4013C6C4C78

Q36404114-15D0A17D-A73E-498E-9FD4-99CD84419E12

Q36404114-2ED514F5-BCB9-4864-B732-50573FEF720E

Q36404114-30F7A9C9-D3CC-40DF-A44C-87F774CF3CC0

Q36404114-4643012B-1ABD-4BD7-B7A5-C8634AFB442D

Q36404114-47672495-0E44-49B2-AB8F-EDB8EC239C99

Q36404114-53A825B9-2515-45FD-9EEA-5FD0016CA48E

Q36404114-545FFA02-EF08-4796-BDD5-81E99339A6CB

P304

Q36404114-F2BB49B9-0BA5-41F5-B529-EA79110AA06D

P31

Q36404114-BA5C62C7-B674-4EF1-B862-C3A2097A7E7D

P356

Q36404114-95BE5B2A-1666-4CD4-B7A6-FC32D4EC91BB

P407

Q36404114-63B08C08-839C-4D6A-B8ED-7FD5F54466C1

P433

Q36404114-CE2B1DE4-5002-4769-840C-B62589449B34

P478

Q36404114-0129A238-6F00-4032-88EA-BAA6B2310234

P50

Q36404114-7E989C18-0468-49EB-B564-C97DBAB143D0

Q36404114-C22FFAFA-C4CF-48B0-8DE6-E8987591E78B

Q36404114-DAB54C5B-2F71-433C-801B-DDFBEAB35ABB

P577

Q36404114-AEB4A113-A027-4CD6-826F-22A7115CDF94

P698

Q36404114-6FC5606A-86AD-4BF1-B1FD-6DF961416954

P932

Q36404114-032CB1D0-1297-42CD-A5B5-A1A86F256A91

P356

P1433

Journal of Clinical Investigation

P1476

Pharmacologic targeting of a s ...... nced bone regeneration in mice

@en

P2093

Chirayu Patel

http://www.w3.org/2001/XMLSchema#string

Dallas C Jones

http://www.w3.org/2001/XMLSchema#string

David T Scadden

http://www.w3.org/2001/XMLSchema#string

Gary Stein

http://www.w3.org/2001/XMLSchema#string

Jane B Lian

http://www.w3.org/2001/XMLSchema#string

Jesse A Schoonmaker

http://www.w3.org/2001/XMLSchema#string

Joshua P Aronson

http://www.w3.org/2001/XMLSchema#string

Julie C Liu

http://www.w3.org/2001/XMLSchema#string

Laurie H Glimcher

http://www.w3.org/2001/XMLSchema#string

Marc N Wein

http://www.w3.org/2001/XMLSchema#string

P2860

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation

Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

Multilineage potential of adult human mesenchymal stem cells

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development

Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation

P304

491-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI33102

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Louise E Purton

Kenneth C Anderson

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18219387

http://www.w3.org/2001/XMLSchema#string

P932

2213372

http://www.w3.org/2001/XMLSchema#string